Skip to main content
    N

    Nephros Inc (NEPH)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ

    $3.58
    +0.06 (+1.70%)

    Market Cap: $38.23M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    63%(19/30)
    Avg Surprise
    +68.53%
    Streak
    8 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$0.03
    Range$0.03 - $0.03
    1 analysts
    EPS RevisionsNo revisions (7d)
    1
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$0.03+20.0%
    60d ago$0.03+20.0%
    30d ago$0.02+50.0%
    7d ago$0.02+28.8%
    Current$0.03
    Revenue Consensus
    $5M
    Range$5M - $6M
    3 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.13
    Range$0.13 - $0.13
    1 analysts
    Revenue Consensus
    $7M
    Range$6M - $7M
    3 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.13---
    Sep 26EST
    		-$0.03---
    Jun 26
    Reported Aug 6
    		$0.06$0.01+500.00%Beat+200.0%
    Mar 26
    Reported May 7
    		$0.01$0.01+0.00%Beat-80.0%
    Dec 25
    Reported Mar 12
    		$0.01$-0.01+200.00%Beat-66.7%
    Sep 25
    Reported Nov 6
    		$0.03$-0.02+250.00%Beat+50.0%
    Jun 25
    Reported Aug 7
    		$0.02$-0.02+200.00%Beat+166.7%
    Mar 25
    Reported May 15
    		$0.05$-0.01+1100.00%Beat+350.0%
    Dec 24
    Reported Mar 24
    		$0.03$-0.01+300.00%Beat+150.0%
    Sep 24
    Reported Nov 7
    		$0.02$-0.02+200.00%Beat+200.0%
    Jun 24
    Reported Aug 8
    		$-0.03$-0.01-200.00%Miss+25.0%
    Mar 24
    Reported May 9
    		$-0.02$-0.04+50.00%Beat+33.3%
    Dec 23
    Reported Mar 7
    		$-0.06$-0.02-200.00%Miss+40.0%
    Sep 23
    Reported Nov 8
    		$-0.02N/A+60.00%Beat+93.5%
    Jun 23
    Reported Aug 9
    		$-0.04$-0.05+20.00%Beat+66.7%
    Mar 23
    Reported May 10
    		$-0.03$-0.02-50.00%Miss+85.0%
    Dec 22
    Reported Mar 8
    		$-0.10$-0.06-66.67%Miss+9.1%
    Sep 22
    Reported Nov 2
    		$-0.31$-0.11-181.82%Miss-158.3%
    Jun 22
    Reported Aug 10
    		$-0.12$-0.14+14.29%Beat+0.0%
    Mar 22
    Reported May 4
    		$-0.20$-0.11-81.82%Miss-81.8%
    Dec 21
    Reported Feb 23
    		$-0.11$-0.11+0.00%Beat-37.5%
    Sep 21
    Reported Nov 4
    		$-0.12$-0.11-9.09%Miss+14.3%
    Jun 21
    Reported Aug 5
    		$-0.12$-0.11-9.09%Miss+36.8%
    Mar 21
    Reported May 6
    		$-0.11$-0.11+0.00%Beat+15.4%
    Dec 20
    Reported Mar 1
    		$-0.08$-0.11+27.27%Beat-300.0%
    Sep 20
    Reported Nov 5
    		$-0.14$-0.14+0.00%Beat-40.0%
    Jun 20
    Reported Aug 5
    		$-0.19$-0.15-26.67%Miss-35.7%
    Mar 20
    Reported May 6
    		$-0.13$-0.09-44.44%Miss+27.8%
    Dec 19
    Reported Feb 27
    		$-0.02N/A+81.82%Beat+77.8%
    Sep 19
    Reported Nov 6
    		$-0.10$-0.10+0.00%Beat-900.0%
    Jun 19
    Reported Aug 7
    		$-0.14$-0.18+22.22%Beat-1300.0%
    Mar 19
    Reported May 8
    		$-0.18$-0.09-100.00%Miss-500.0%
    Dec 18
    Reported Mar 12
    		$-0.09N/AN/ABeat-550.0%
    Sep 18
    Reported Nov 8
    		$-0.01N/AN/ABeat+0.0%
    Jun 18
    Reported Aug 8
    		$-0.01N/AN/ABeat+0.0%
    Mar 18
    Reported May 9
    		$-0.03N/AN/ABeat-200.0%
    Dec 17
    Reported Feb 26
    		$0.02N/AN/ABeat+116.9%
    Sep 17
    Reported Nov 9
    		$-0.01N/AN/ABeat-
    Jun 17
    Reported Aug 8
    		$-0.01N/AN/ABeat-
    Mar 17
    Reported May 9
    		$-0.01N/AN/ABeat-
    Dec 16
    Reported Mar 20
    		$-0.12N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio32.55EV/EBITDA20.17x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin8.38%Operating Margin20.20%
    ROE16.10%ROIC10.15%
    Financial Health
    Debt/Equity0.04xInterest Coverage1068.00x
    Current Ratio4.07xQuick Ratio2.71x
    Trading Statistics
    Beta1.64Avg Volume36.61K
    52-Week High$6.4252-Week Low$2.66

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$3.45
    SMA 20$3.77
    SMA 50$4.10
    SMA 200$3.74
    EMA 10$3.56
    EMA 20$3.71
    EMA 50$3.87
    EMA 200$3.80

    MACD

    Line: -0.19Signal: -0.18Hist: -0.00

    ADX

    ADX: 29.8+DI: 15.8-DI: 25.1

    Aroon & PSAR

    Aroon Up4.0
    Aroon Down72.0
    PSAR$3.01

    Bollinger Bands

    Upper Band$4.55
    Lower Band$2.98
    %B Position4175%(Upper)
    Band Width0.38

    RSI (14-Day)

    Neutral
    43.9

    Momentum Oscillators

    Stoch %K40.7
    Stoch %D40.6
    Williams %R-58.1
    ROC (10d)-2.5%
    Momentum-0.09
    CCI (20d)-47.5
    MFI (14d)21.4

    Volatility Measures

    ATR (14d)$0.30(8.3%)
    StdDev (20d)0.39
    Hist Vol76.3%(High)

    Volume Flow

    VWAP$3.55
    OBV-237.3K
    AD Line-1.2M
    CMF (20d)-0.124

    Volume Metrics

    Avg Vol (20d)38.5K
    Vol Ratio0.7x
    VWMA (20d)$3.49

    Pivot Points

    R3$3.86
    R2$3.72
    R1$3.62
    Pivot Point$3.47
    S1$3.38
    S2$3.23
    S3$3.13

    Advanced Oscillators

    TSI-19.02
    Ultimate Osc54.2
    KST-185.46

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$6.02M$5.21M$4.73M$4.76M$4.42M$4.88M$3.87M$3.52M$3.25M$3.52M$3.25M$3.74M
    Cost of Revenue$1.99M$2.22M$1.97M$1.85M$1.62M$1.72M$1.40M$1.37M$1.34M$1.33M$1.23M$1.55M
    Gross Profit$4.03M$2.99M$2.76M$2.92M$2.79M$3.15M$2.48M$2.15M$1.91M$2.19M$2.02M$2.19M
    Operating Expenses$2.81M$2.90M$2.74M$2.60M$2.55M$2.59M$2.16M$1.94M$2.23M$2.39M$2.67M$2.40M
    R&D$366,000$346,000$395,000$338,000$311,000$295,000$252,000$188,000$254,000$212,000$208,000$205,000
    SG&A$2.42M$2.52M$2.32M$2.23M$2.20M$2.25M$1.87M$1.72M$1.94M$2.14M$2.41M$2.14M
    Operating Income$1.21M$97,000$18,000$314,000$248,000$566,000$317,000$206,000$-317,000$-200,000$-649,000$-203,000
    Interest Income$30,000$32,000$54,000$41,000$31,000$13,000$28,000$20,000$21,000$25,000$28,000$11,000
    Interest Expense$1,000$0$0$0$1,000$8,000$0$0$0$1,000$1,000$0
    Income Before Tax$1.21M$140,000$62,000$340,000$246,000$558,000$364,000$183,000$-289,000$-169,000$-654,000$-182,000
    Income Tax Expense$13,000$0$0$3,000$9,000$0$0$0$0$0$0$0
    Net Income$1.20M$140,000$70,000$337,000$237,000$558,000$318,000$183,000$-289,000$-138,000$-654,000$-182,000
    EBITDA$1.21M$135,000$40,000$333,000$249,000$585,000$371,000$196,000$-275,000$-159,000$-630,000$-137,000
    EBIT$1.18M$108,000$8,000$299,000$216,000$545,000$336,000$163,000$-310,000$-193,000$-681,000$-193,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about NEPH

    Government Contracts

    Gov Obligations (TTM)
    $0
    Gov Obligations / Revenue
    0.0%
    Obligations YoY
    N/A
    Active Awards
    0
    New Awards (TTM)
    0
    Avg Remaining Term
    N/A

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Form DEF 14A NEPHROS INC For: Oct 14

    This DEF 14A filing by NEPHROS INC details the proxy statement for its Annual Meeting of Stockholders on November 25, 2026. Key proposals include the election of two directors, ratification of Baker Tilly US...

    StreetInsider•10/14/26•Neutral

    Nephros Announces Virtual 2026 Annual Meeting for November 25 with Updated Stockholder Deadlines

    Nephros, Inc. has scheduled its 2026 Annual Meeting of Stockholders for November 25, 2026, to be held virtually. The company has set September 30, 2026...

    Kalkine Media•10/13/26•Neutral

    Nephros Q2 2026 Earnings Call: Complete Transcript

    Nephros Inc. reported record Q2 2026 revenue of $6 million, a 36% year-over-year increase, driven by double-digit growth in programmatic product revenue and nearly tripled service-only revenue. The company achieved a 67%...

    Benzinga•9/17/26•Bullish

    NEPHROS INC (NASDAQ: NEPH) Director Amron Arthur H Executes 43,295 Share Transactions

    NEPHROS INC director Amron Arthur H executed transactions involving 43,295 shares of the company stock across three trades on September 14, 2026. The share prices ranged from $0 to $3.95...

    Kalkine Media•9/17/26•Neutral

    Nephros, Inc. Delivers Record Quarter Amid Margin Strain

    Nephros, Inc. reported record Q2 2026 revenue of $6.0M, a 36% year-over-year increase, and significantly higher profitability...

    The Globe and Mail•8/24/26•Somewhat-Bullish

    NEPH Valuation and Fair Value

    P/E
    32.5x
    EV/EBITDA
    20.2x
    PEG
    0.0x
    P/B
    3.2x
    See GNG's fair value

    NEPH Profitability: Margins, ROIC and FCF

    Gross margin
    61.3%
    Operating margin
    20.2%
    Net margin
    8.4%
    ROIC
    10.1%
    ROE
    16.1%
    FCF margin
    -3.2%

    NEPH Competitors

    CompanyTicker
    Cosmos Health Inc.COSM
    Veru IncVERU
    FibroGen IncFGEN
    Harvard Bioscience IncHBIO
    CVRx IncCVRX
    Incannex Healthcare Inc.IXHL
    Scynexis IncSCYX
    Star Equity Holdings IncSTRR

    Sector: Healthcare

    NEPH Analyst Ratings

    Consensus
    Buy
    Analysts
    3
    Strong Buy
    2
    Buy
    0
    Hold
    1
    Sell
    0
    Strong Sell
    0

    NEPH Bull Case vs Bear Case

    Bull case

    • NEPH beat EPS estimates in 87.5% of its last 8 reported quarters.
    • NEPH grew quarterly revenue 36.2% year over year.

    NEPH Earnings: Beat Rate and Next Report

    Beat rate
    7 of 8 quarters (87.5%)
    Average surprise
    343.8%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $0.03
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 1 down

    Frequently Asked Questions About NEPH

    Does NEPH pay dividends?

    Nephros Inc (NEPH) does not currently pay a regular dividend.

    What is NEPH's P/E ratio?

    Nephros Inc has a price-to-earnings (P/E) ratio of 32.55.

    What is NEPH's market cap?

    Nephros Inc (NEPH) has a market capitalization of $38.23M with a current stock price of $3.58.

    Related stocks

    Sector: Healthcare

    All stocks starting with N

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In